Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).
暂无分享,去创建一个
S. Lipshultz | M. Borowitz | M. Devidas | J. Pullen | B. Camitta | R. Hutchison | B. Asselin | Chenguang Wang
[1] D. Neuberg,et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.
[2] S. Perkins,et al. High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971 , 2008 .
[3] N. Heerema,et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.
[4] M. Schrappe,et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Holdsworth,et al. Antimetabolite‐based therapy in childhood T‐cell acute lymphoblastic leukemia: A report of POG study 9296 , 2006, Pediatric blood & cancer.
[6] P. Nathan,et al. Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P , 2006, Leukemia & lymphoma.
[7] J. Kurtzberg,et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Campana,et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR , 2005, British journal of haematology.
[9] M. Relling,et al. Moving towards individualized medicine with pharmacogenomics , 2004, Nature.
[10] R. Gelber,et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Peto,et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[13] W. Hop,et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. , 2002, Blood.
[14] Mary V. Relling,et al. Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.
[15] J. Harbott,et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.
[16] W. Hiddemann,et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.
[17] M. Tiemann,et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. , 2000, Blood.
[18] A. Look,et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study , 1999, Leukemia.
[19] M. Amylon,et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.
[20] H. Sather,et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.
[21] N. Heerema,et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. , 1998, Blood.
[22] M. Schrappe,et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Sather,et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.
[24] C. C. Bailey,et al. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X , 1995, The Lancet.
[25] M. Relling,et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. , 1994, The Journal of clinical investigation.
[26] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[27] M. Relling,et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia , 1994 .
[28] R. Gelber,et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Reaman,et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] F. Behm,et al. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.
[31] C. Pui,et al. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. , 1992, Leukemia.
[32] R. Gelber,et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). , 1991, Blood.
[33] Denis R. Miller,et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure , 1991, Cancer.
[34] C. Pui,et al. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. , 1990, Blood.
[35] J. Shuster,et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. , 1990, Blood.
[36] J. Shuster,et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. , 1988, Blood.
[37] M. Borowitz,et al. Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen‐positive childhood T‐cell leukemia A pediatric oncology group study , 1987, Cancer.
[38] M. Borowitz,et al. Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] K. Starling,et al. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). , 1982, Blood.
[40] L. Borella,et al. Clinical importance of lymphoblasts with T markers in childhood acute leukemia. , 1975, The New England journal of medicine.
[41] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[42] R. Gelber,et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] F. Behm,et al. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay , 2001, Leukemia.
[44] A. Moghrabi,et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995) , 2000, Leukemia.
[45] M. Relling,et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.
[46] James T. Lin,et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. , 1993, Leukemia.
[47] J. Borsi,et al. Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. , 1990, Pediatric hematology and oncology.
[48] F. Behm,et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. , 1990, Blood.
[49] G. Henze,et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990, Haematology and blood transfusion.
[50] Jonathan J. Shuster,et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study , 1990 .